Orthofix Medical (NASDAQ:OFIX) Posts Earnings Results

Orthofix Medical (NASDAQ:OFIX - Get Free Report) issued its earnings results on Tuesday. The medical device company reported ($0.75) EPS for the quarter, missing analysts' consensus estimates of $0.06 by ($0.81), Zacks reports. The company had revenue of $215.66 million during the quarter, compared to the consensus estimate of $212.72 million. Orthofix Medical had a negative return on equity of 21.25% and a negative net margin of 15.18%. Orthofix Medical updated its FY 2025 guidance to EPS.

Orthofix Medical Stock Up 1.0 %

Shares of OFIX traded up $0.17 during mid-day trading on Friday, hitting $17.38. The company's stock had a trading volume of 203,764 shares, compared to its average volume of 178,304. The company's 50-day moving average is $17.93 and its 200-day moving average is $17.35. Orthofix Medical has a 52-week low of $12.08 and a 52-week high of $20.73. The firm has a market capitalization of $664.16 million, a price-to-earnings ratio of -5.55 and a beta of 1.10. The company has a current ratio of 2.39, a quick ratio of 1.11 and a debt-to-equity ratio of 0.25.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. Stifel Nicolaus upgraded shares of Orthofix Medical from a "hold" rating to a "buy" rating and upped their target price for the stock from $18.00 to $24.00 in a research note on Friday, November 8th. StockNews.com upgraded shares of Orthofix Medical from a "hold" rating to a "buy" rating in a research note on Tuesday. Roth Mkm restated a "buy" rating and issued a $22.00 target price on shares of Orthofix Medical in a research note on Wednesday. Finally, Canaccord Genuity Group reaffirmed a "buy" rating and issued a $24.00 price target on shares of Orthofix Medical in a research report on Wednesday. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, Orthofix Medical has a consensus rating of "Moderate Buy" and a consensus price target of $23.33.

Remove Ads

Insider Transactions at Orthofix Medical

In related news, CEO Massimo Calafiore sold 9,203 shares of the stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $17.14, for a total transaction of $157,739.42. Following the completion of the sale, the chief executive officer now owns 124,151 shares of the company's stock, valued at $2,127,948.14. This represents a 6.90 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Julie Andrews sold 4,655 shares of the stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $17.89, for a total transaction of $83,277.95. Following the sale, the chief financial officer now directly owns 28,312 shares of the company's stock, valued at $506,501.68. The trade was a 14.12 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 25,442 shares of company stock valued at $436,883. Company insiders own 2.60% of the company's stock.

Orthofix Medical Company Profile

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.